Novo Nordisk Shares Jump 9% in a Week as Buyback, Pill Approval, and Court Win Converge

Danish pharma giant Novo Nordisk's B-shares gain 9% driven by South African court injunction against copycats, oral Wegovy approval, accelerated buyback, but profit decline and data breach loom.

The Danish pharmaceutical giant has engineered a broad-based recovery, with multiple catalysts aligning to lift its stock. Novo Nordisk’s B-shares closed at €40.06 on Monday before climbing to €40.81, marking a near-9% gain over the past seven days. The rally draws on a South African court victory, fresh regulatory approvals for its oral Wegovy pill, promising pipeline data, and an accelerated share buyback programme. Yet the broader picture remains clouded by an expected profit decline and a recent data breach.

Legal victory strikes at copycat drugs

The most potent short-term catalyst came from the Gauteng High Court in South Africa on 22 June. The court issued an interim injunction against iDexis, barring the company from manufacturing, distributing, or marketing unapproved semaglutide products. Crucially, the judges rejected iDexis’s argument that pharmaceutical compounding exemptions apply to chemically similar substances, ruling that such exemptions only cover identical active ingredients. The order remains in place until the South African Health Products Regulatory Authority (SAHPRA) completes its investigation — a move that secures Novo Nordisk’s intellectual property in a key emerging market.

Buyback programme accelerates

Novo Nordisk has been aggressively repurchasing its own shares under a programme running until February 2027, with a maximum allocation of 11.2 billion Danish kroner. Between 15 and 19 June alone, the company bought back roughly 1.075 million B-shares for around 308 million DKK. Since the programme’s launch in February 2026, Novo Nordisk has acquired just over 20.9 million shares at an average price of 266.09 DKK, leaving the company holding nearly 1% of its total share capital in treasury.

Institutional investors have shown a mixed response. Dodge & Cox added 19.3 million shares in the first quarter, while Susquehanna increased its stake by 9.9 million. FMR LLC, on the other hand, trimmed its position by 8.7 million shares, reflecting divergent views on the stock’s near-term trajectory.

Wegovy pill gains traction on both sides of the Atlantic

The commercial pipeline is also delivering fresh momentum. Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) greenlit the oral Wegovy pill as a daily weight-loss treatment in mid-June. In the US, the drug has already racked up over three million prescriptions in just five months, with many patients starting a GLP-1 therapy for the first time. Additionally, new data presented at the European Congress on Obesity showed that early responders to the high-dose Wegovy formulation achieved an average weight reduction of 27.7%, compared with 15.4% for other patient groups. Meanwhile, the market expects Novo Nordisk to submit the oral formulation for approval in China in the coming months.

On the market-access front, CVS Health has expanded its GLP-1 support programmes. Medicare patients will now pay a maximum of $50 per month, and virtual weight-management consultations are available for $49, broadening the reach of Wegovy to a wider patient population.

CagriSema data strengthens hand against Eli Lilly

The phase 3 REIMAGINE trial for CagriSema — a combination of cagrilintide and semaglutide — delivered statistically significant reductions in both blood glucose and body weight in adults with type 2 diabetes. These results bolster Novo Nordisk’s competitive position against Eli Lilly in the increasingly crowded metabolic disease market.

Technical picture brightens but remains fragile

The stock now trades about 7.8% above its 50-day moving average, a bullish short-term signal. However, it remains roughly 10% below its year-to-date start and 34% below its 52-week high of €61.20. On the weekly chart, the next major resistance lies at the 200-day moving average of €41.05. A decisive break above that level would materially improve the technical outlook. Over a 12-month horizon, the shares are still down around 32%, underscoring the depth of the earlier sell-off.

Analyst support offsets lingering headwinds

Berenberg reaffirmed its buy rating and lifted its price target to 325 DKK, signalling confidence in the company’s pipeline and market position. Yet two concrete risks limit upside. For fiscal 2026, Novo Nordisk expects revenue and profit to decline by 4% to 12%. Compounding that, a data leak exposed 1.1 terabytes of corporate information. Whether the breach erodes institutional investor confidence will become clearer when the next quarterly report is released. For now, the stock’s rally shows that the market is weighing the near-term catalysts more heavily than the structural challenges ahead.